These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8782017)

  • 21. Relationship between CD38 expression on peripheral blood T-cells and monocytes, and response to antiretroviral therapy: a one-year longitudinal study of a cohort of chronically infected ART-naive HIV-1+ patients.
    Almeida M; Cordero M; Almeida J; Orfao A
    Cytometry B Clin Cytom; 2007 Jan; 72(1):22-33. PubMed ID: 17051525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD4+ T cell receptor repertoire perturbations in HIV-1 infection: association with plasma viremia and disease progression.
    Malhotra U; Huntsberry C; Holte S; Lee J; Corey L; McElrath MJ
    Clin Immunol; 2006 Apr; 119(1):95-102. PubMed ID: 16403675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
    Zaunders JJ; Cunningham PH; Kelleher AD; Kaufmann GR; Jaramillo AB; Wright R; Smith D; Grey P; Vizzard J; Carr A; Cooper DA
    J Infect Dis; 1999 Aug; 180(2):320-9. PubMed ID: 10395845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IL-2 taken to HAART.
    Gilden D
    GMHC Treat Issues; 1999 Feb; 13(2):4-6. PubMed ID: 11366116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.
    Abbas UL; Mellors JW
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13377-8. PubMed ID: 12370421
    [No Abstract]   [Full Text] [Related]  

  • 26. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 load quantitation: a 17-year perspective.
    Holodniy M
    J Infect Dis; 2006 Sep; 194 Suppl 1():S38-44. PubMed ID: 16921471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [T-20: a fusion inhibitor].
    Iafolla M
    Sidahora; 2002; (3):20-2. PubMed ID: 12703471
    [No Abstract]   [Full Text] [Related]  

  • 29. Valproic acid: a potential role in treating latent HIV infection.
    Routy JP
    Lancet; 2005 Aug 13-19; 366(9485):523-4. PubMed ID: 16099272
    [No Abstract]   [Full Text] [Related]  

  • 30. [HIV-1 eradication with the "shock and kill" strategy].
    Schiedel M
    Pharm Unserer Zeit; 2010 May; 39(3):171-3. PubMed ID: 20425765
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of HIV-infection by means of gene therapy].
    Glazkova DV; Bogoslovskaia EV; Markelov ML; Shipulin GA; Pokrovskiĭ VV
    Vestn Ross Akad Med Nauk; 2012; (5):16-23. PubMed ID: 22856163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Anti-HIV drugs work rapidly or not at all. Virus dynamics--therapeutic consequences].
    Aulehla S
    Fortschr Med; 1995 Apr; 113(12):14-6. PubMed ID: 7789929
    [No Abstract]   [Full Text] [Related]  

  • 33. Instantaneous inhibitory potential and inhibitory quotient show a modest association with virologic outcome: is either a useful surrogate for clinical drug efficacy?
    MacArthur RD
    Clin Infect Dis; 2010 Jul; 51(1):99-100. PubMed ID: 20504164
    [No Abstract]   [Full Text] [Related]  

  • 34. HIV infection: how effective is drug combination treatment?
    Grossman Z; Feinberg M; Kuznetsov V; Dimitrov D; Paul W
    Immunol Today; 1998 Nov; 19(11):528-32. PubMed ID: 9818549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapeutic interventions targeting HIV interactions with host-associated carbohydrates.
    McReynolds KD; Gervay-Hague J
    Chem Rev; 2007 May; 107(5):1533-52. PubMed ID: 17439183
    [No Abstract]   [Full Text] [Related]  

  • 36. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy.
    Greub G; Cozzi-Lepri A; Ledergerber B; Staszewski S; Perrin L; Miller V; Francioli P; Furrer H; Battegay M; Vernazza P; Bernasconi E; Günthard HF; Hirschel B; Phillips AN; Telenti A;
    AIDS; 2002 Sep; 16(14):1967-9. PubMed ID: 12351960
    [No Abstract]   [Full Text] [Related]  

  • 37. Fostemsavir: a new CD4 attachment inhibitor.
    Cahn P; Fink V; Patterson P
    Curr Opin HIV AIDS; 2018 Jul; 13(4):341-345. PubMed ID: 29771694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stubborn AIDS reservoirs vulnerable to new treatments.
    Cohen J
    Science; 1997 May; 276(5314):898-9. PubMed ID: 9163035
    [No Abstract]   [Full Text] [Related]  

  • 39. Promising anti-HIV compounds in preclinical or early clinical development.
    Litterst C
    Adv Exp Med Biol; 1996; 394():397-404. PubMed ID: 8815704
    [No Abstract]   [Full Text] [Related]  

  • 40. COVID-19 and AIDS: Outcomes from the coexistence of two global pandemics and the importance of chronic antiretroviral therapy.
    Patel RH; Acharya A; Mohan M; Byrareddy SN
    J Med Virol; 2021 Feb; 93(2):641-643. PubMed ID: 32779740
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.